Pfizer Inc. Reveals Their Findings on New Cachexia Drug
Pfizer Inc. has just announced their results from a Phase 2 study of one of their new drugs, ponsegromab, which is a monoclonal antibody. It’s role is targeting the growth differentiation factor-15 (GDF-15) in patients with cancer cachexia.
Read more...